Autologous formalin-fixed tumor vaccine for initially-diagnosed glioblastoma

Takashi Maruyama, Yoshihiro Muragaki, Eiichi Ishikawa, Koji Tsuboi, Hiroshi Iseki, Tadao Ohno, Akira Matsumura, Yoshikazu Okada

研究成果: Article査読

抄録

There has been little improvement in the prognosis of glioblastoma multiforme (GBM) despite a number of therapeutic modalities that have been developed. Immunotherapy presents a therapeutic challenge with a different strategy from radiation therapy and chemotherapy. Based on the tumor-specific immune reactions, Ohno's group developed the use of formalin-fixed sections instead of live target tumor cells and formulated an autologous formalin-fixed tumor vaccine (AFTV). This paper reports the results of preliminary clinical trials and prospective clinical trial directed to the evaluation of the therapeutic efficacy of the AFTV concomitant with fractionated radiotherapy (FRT) in cases of initially-diagnosed glioblastoma multiforme (GBM).

本文言語English
ページ(範囲)448-455
ページ数8
ジャーナルBiotherapy
24
6
出版ステータスPublished - 2010 11
外部発表はい

ASJC Scopus subject areas

  • 腫瘍学
  • 癌研究

フィンガープリント

「Autologous formalin-fixed tumor vaccine for initially-diagnosed glioblastoma」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル